Previous 10 | Next 10 |
Stockholders From Both Assertio and Spectrum Have Overwhelmingly Voted in Support of the Transaction Transaction Expected to be Significantly Accretive to Assertio in 2024 LAKE FOREST, Ill. and BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertioȁ...
2023-07-26 03:37:48 ET Summary The stock is down 33% from its 52-week high. Q2 revenue estimates are low. Lead product’s use may be expanding. Recently acquired drug almost exceeded yearly guidance in two quarters. Assertio Holdings ( ASRT ), the small...
LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release second quarter 2023 financia...
2023-07-24 04:56:40 ET Summary Spectrum stockholders will receive contingent value rights, too, along with Assertio shares. The rewards are payable on achievement of 2024 and 2025 sales levels from Spectrum's lead drug. Rolvedon has already reached the first (hardest) target i...
2023-07-19 03:24:29 ET Summary Assertio Holdings showed Q1 2023 net product sales increase of 18%, despite reporting a net loss due to increased expenses. Assertio's growth strategy involves expanding product range through acquisitions; plans to acquire Spectrum Pharmaceuticals ar...
2023-07-07 09:16:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Supreme Court recently nullified the Biden administration’s proposed student loan forgiveness program in a 6-3 ruling. Seen as overreaching the authority of the executive branch, thi...
2023-06-26 07:48:05 ET Specialty pharmaceutical company Assertio Holdings ( NASDAQ: ASRT ) said on Monday that it has joined the broad-market Russell 3000 index as part of the 2023 reconstitution. The addition is effective from June 23 market close. Source: Press Release...
LAKE FOREST, Ill., June 26, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company, today announced that it has joined the broad-market Russell 3000 Index as part of the 2023 reconstitution, com...
2023-06-22 19:46:02 ET Summary Spectrum and Assertio's merger would lead to a diversified product portfolio and a combination of two unique marketing strategies. Spectrum's ROLVEDON has the potential to become the standard of care for reducing chemotherapy-induced neutropenia in a...
2023-06-20 01:55:13 ET Summary Assertio is a late-stage pharmaceutical company that has shown significant growth and cost savings under new leadership, focusing on a low-cost, data-driven marketing model. The company's leading product, Indocin, has seen increased sales and a recen...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...
LAKE FOREST, Ill., May 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that its Board of...